De Lima José Rivaldo, Da Silva Góes Alexandre José, De Oliveira Borba Elizabeth Fernanda, da Silva Meykson Alexandre, Caiana Rodrigo Ribeiro Alves, Rodrigues Maria do Desterro, De Lima Silva Mariza Severina, Chagas Cristiano Aparecido, Baratte Blandine, Robert Thomas, Bach Stéphane, Ourliac-Garnier Isabelle, Marchand Pascal, Da Silva Teresinha Gonçalves
Departamento de Antibióticos, Universidade Federal de Pernambuco, Recife 50670-420, Brazil.
Centro Acadêmico de Vitória, Universidade Federal de Pernambuco, Vitória de Santo Antão 55608-680, Brazil.
Pharmaceuticals (Basel). 2025 Jun 3;18(6):837. doi: 10.3390/ph18060837.
β-Lapachone (β-lap) is an -naphthoquinone with potent antitumor activity. However, its clinical application is hindered by poor solubility and toxicity. Thiosemicarbazone derivatives of β-lap (BV3 and BV5) have demonstrated enhanced selectivity and anticancer efficacy in leukemia cells. Therefore, this study aimed to evaluate the therapeutic potential of these derivatives in solid tumors. Furthermore, the mechanism of tumor cell death, the involvement of protein kinase inhibition, and the toxicogenetic safety of BV3 and BV5 were investigated. : The cytotoxic effects of BV3 and BV5 were assessed in cancer cell lines and a non-cancerous cell line. The compounds were most effective against HeLa (human cervical adenocarcinoma) cells. For that reason, this type of cell was chosen to study how the compounds might cause cell death, using flow cytometry. Kinase inhibition assays were conducted in vitro and in silico, followed by genotoxicity assessments to determine toxicogenetic safety. : BV3 and BV5 derivatives significantly inhibited cancer cell proliferation after 72 h, with IC values ranging from 2.8 to 36.9 µM. BV3 demonstrated superior selectivity (selectivity index: 15.6) when compared to β-lap (selectivity index: 1.9) in HeLa cells. Morphological changes and flow cytometry analysis revealed features of apoptosis and/or necrosis in HeLa cells treated with the compounds BV3 and BV5. Furthermore, among the kinases tested, BV3 and BV5 were more effective in inhibiting the activity of the protein kinases JAK3 and GSK3β. This result was also confirmed by the in silico studies. Additionally, genotoxicity assays indicated an overall favorable toxicogenetic safety profile; however, BV5 exhibited potential genotoxicity at high concentrations. : The findings underscore the anticancer potential of BV3 and BV5 in solid tumors and highlight their mechanism of action, which involves protein kinases. The findings also show that the drugs are selective and relatively safe.
β-拉帕醌(β-lap)是一种具有强大抗肿瘤活性的萘醌。然而,其临床应用因溶解性差和毒性而受到阻碍。β-拉帕醌的硫代半卡巴腙衍生物(BV3和BV5)在白血病细胞中显示出增强的选择性和抗癌功效。因此,本研究旨在评估这些衍生物在实体瘤中的治疗潜力。此外,还研究了肿瘤细胞死亡的机制、蛋白激酶抑制的参与情况以及BV3和BV5的毒理遗传学安全性。:在癌细胞系和非癌细胞系中评估了BV体的细胞毒性作用。这些化合物对HeLa(人宫颈腺癌)细胞最有效。因此,选择这种类型的细胞,使用流式细胞术来研究这些化合物可能如何导致细胞死亡。在体外和计算机模拟中进行了激酶抑制试验,随后进行遗传毒性评估以确定毒理遗传学安全性。:BV3和BV5衍生物在72小时后显著抑制癌细胞增殖,IC值范围为2.8至36.9μM。与HeLa细胞中的β-拉帕醌(选择性指数:1.9)相比,BV3表现出更高的选择性(选择性指数:15.6)。形态学变化和流式细胞术分析揭示了用化合物BV3和BV5处理的HeLa细胞中凋亡和/或坏死特征。此外,在所测试的激酶中,BV3和BV5在抑制蛋白激酶JAK3和GSK3β的活性方面更有效。计算机模拟研究也证实了这一结果。此外,遗传毒性试验表明总体毒理遗传学安全性良好;然而,BV5在高浓度下表现出潜在的遗传毒性。:这些发现强调了BV3和BV5在实体瘤中的抗癌潜力,并突出了它们涉及蛋白激酶的作用机制。这些发现还表明这些药物具有选择性且相对安全。